Importer of Controlled Substances; Notice of Application; SA INTL GMBH C/O., Sigma Aldrich Co. LLC, 19015-19016 [2013-07152]

Download as PDF 19015 Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices recommend that the Respondent’s DEA Certificate of Registration, Number BJ5128067, be revoked.5 DEPARTMENT OF JUSTICE Dated: February 12, 2013. Gail A. Randall, Administrative Law Judge. Importer of Controlled Substances; Notice of Application; SA INTL GMBH C/O., Sigma Aldrich Co. LLC [FR Doc. 2013–07195 Filed 3–27–13; 8:45 am] Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on February 1, 2013, SA INTL GMBH C/O., Sigma Aldrich Co. LLC., 3500 Dekalb Street, St. Louis, Missouri 63118, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances: BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application; Stepan Company Drug Enforcement Administration Drug This is notice that on February 6, 2013, Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of Coca Leaves (9040), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance to manufacture bulk controlled substance for distribution to its customer. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: March 19, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. mstockstill on DSK4VPTVN1PROD with NOTICES [FR Doc. 2013–07147 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P 5 The sole basis of my recommendation is the loss of Respondent’s state licensure. I make no findings or conclusions concerning the other allegations asserted in the Order to Show Cause. VerDate Mar<15>2010 20:20 Mar 27, 2013 Jkt 229001 Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ Aminorex (1585) ........................... Gamma Hydroxybutyric Acid (2010). Methaqualone (2565) ................... Alpha-ethyltryptamine (7249) ....... Ibogaine (7260) ............................ Lysergic acid diethylamide (7315) Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). 4-Methoxyamphetamine (7411) ... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 1-[1-(2Thienyl)cyclohexyl]piperidine (7470). N-Benzylpiperazine (7493) ........... Heroin (9200) ............................... Normorphine (9313) ..................... Etonitazene (9624) ....................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Nabilone (7379) ............................ Phencyclidine (7471) .................... PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Opium, powdered (9639) ............. Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II II II II II II The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417(2007). In regard to the non-narcotic raw material, any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 29, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import basic classes of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of E:\FR\FM\28MRN1.SGM 28MRN1 19016 Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. CFR § 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–07150 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2013–07152 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; Mylan Pharmaceuticals, Inc. Importer of Controlled Substances; Notice of Registration; Johnson Matthey, Inc. By Notice dated November 19, 2012, and published in the Federal Register on November 27, 2012, 77 FR 70824, Johnson Matthey, Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Drug Schedule mstockstill on DSK4VPTVN1PROD with NOTICES Coca Leaves (9040) ..................... Thebaine (9333) ........................... Opium, raw (9600) ....................... Noroxymorphone (9668) .............. Poppy Straw Concentrate (9670) II II II II II The company plans to import the listed controlled substances as raw materials, to be used in the manufacture of bulk controlled substances, for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Johnson Matthey, Inc., to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Johnson Matthey, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 VerDate Mar<15>2010 20:20 Mar 27, 2013 Jkt 229001 By Notice dated November 27, 2012, and published in the Federal Register on December 5, 2012, 77 FR 72409, Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Road, Morgantown, West Virginia 26505, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Drug Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Oxycodone (9143) ........................ Hydromorphone (9150) ................ Methadone (9250) ........................ Morphine (9300) ........................... Fentanyl (9801) ............................ II II II II II II II The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company’s own domestically-manufactured FDF. This analysis is required to allow the company to export domesticallymanufactured FDF to foreign markets. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Mylan Pharmaceuticals, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Mylan Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and PO 00000 Frm 00063 Fmt 4703 Sfmt 9990 local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–07143 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Patheon Pharmaceuticals, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 22, 2013, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 28, 2013. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–07138 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Pages 19015-19016]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07152]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; SA INTL 
GMBH C/O., Sigma Aldrich Co. LLC

    Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this 
is notice that on February 1, 2013, SA INTL GMBH C/O., Sigma Aldrich 
Co. LLC., 3500 Dekalb Street, St. Louis, Missouri 63118, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as an importer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
Aminorex (1585)............................  I
Gamma Hydroxybutyric Acid (2010)...........  I
Methaqualone (2565)........................  I
Alpha-ethyltryptamine (7249)...............  I
Ibogaine (7260)............................  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (MDMA)     I
 (7405).
4-Methoxyamphetamine (7411)................  I
Bufotenine (7433)..........................  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
1-[1-(2-Thienyl)cyclohexyl]piperidine        I
 (7470).
N-Benzylpiperazine (7493)..................  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Etonitazene (9624).........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Nabilone (7379)............................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Ecgonine (9180)............................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Opium, powdered (9639).....................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
sale to research facilities for drug testing and analysis.
    In reference to drug codes 7360 and 7370, the company plans to 
import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No 
other activity for this drug code is authorized for this registration.
    Comments and requests for hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417(2007).
    In regard to the non-narcotic raw material, any bulk manufacturer 
who is presently, or is applying to be, registered with DEA to 
manufacture such basic classes of controlled substances listed in 
schedules I or II, which fall under the authority of section 
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than April 29, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import basic classes of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of

[[Page 19016]]

Diversion Control, Drug Enforcement Administration, that the 
requirements for such registration pursuant to 21 U.S.C. 958(a); 21 
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are 
satisfied.

    Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-07152 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P